SABCS: Pharmas show their working in HR+/HER2- breast cancer
Pharma Phorum
DECEMBER 12, 2022
There was also new data from the monarchE trial of Eli Lilly’s CDK 4/6 inhibitor Verzenio (abemaciclib) in combination with endocrine therapy as an adjuvant treatment for patients with high risk, early-stage HR+/HER2- breast cancer.
Let's personalize your content